SCHEMBL2030290

SCHEMBL2030290

CC[C@@H]1C(=O)N(C)c2cnc(-c3ccncc3N)nc2N1C(C)C

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 17/20 0.57
PLK2 Q9NYY3 14/20 0.57
PLK3 Q9H4B4 4/20 0.57
BRD4 O60885 2/20 0.42
STK4 Q13043 2/20 0.39
PDXK O00764 1/20 0.38
WEE1 P30291 1/20 0.38
NEK3 P51956 1/20 0.38
PTK2 Q05397 1/20 0.38
BRDT Q58F21 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030292 1.00 PLK1 (0.57) PLK1PLK2PLK3BRD4STK4
SCHEMBL2032071 0.88 PLK1 (0.56) PLK1PLK2PLK3BRD4STK4
SCHEMBL2032070 0.88 PLK1 (0.56) PLK1PLK2PLK3BRD4STK4
SCHEMBL16405182 0.87 BRD4 (0.43) PLK1PLK2PLK3BRD4STK4
SCHEMBL2031358 0.85 PLK1 (0.61) PLK1PLK2PLK3BRD4PDXK
SCHEMBL2031359 0.85 PLK1 (0.61) PLK1PLK2PLK3BRD4PDXK
SCHEMBL2030843 0.84 PLK1 (0.58) PLK1PLK2PLK3BRD4STK4
SCHEMBL2030847 0.84 PLK1 (0.58) PLK1PLK2PLK3BRD4STK4
SCHEMBL2030617 0.83 PLK1 (0.53) PLK1PLK2PLK3BRD4STK4
SCHEMBL2030482 0.83 PLK1 (0.53) PLK1PLK2PLK3BRD4STK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516441-B1 PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE ELAN PHARM INC (US) 2015-01-21 EP disclosed
EP-2516441-B1 PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE ELAN PHARM INC (US) 2015-01-21 EP disclosed
US-20130331376-A1 INHIBITORS OF POLO-LIKE KINASE Elan Corporation, Inc. (US) 2013-12-12 US disclosed
US-8541418-B2 Inhibitors of polo-like kinase ELAN PHARMACEUTICAL, INC. (US) 2013-09-24 US disclosed
US-8541418-B2 Inhibitors of polo-like kinase ELAN PHARMACEUTICAL, INC. (US) 2013-09-24 US disclosed
US-8541418-B2 Inhibitors of polo-like kinase ELAN PHARMACEUTICAL, INC. (US) 2013-09-24 US disclosed
EP-2516441-A1 PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE Elan Pharmaceuticals Inc. (US) 2012-10-31 EP disclosed
US-20110207716-A1 INHIBITORS OF POLO-LIKE KINASE ELAN PHARMACEUTICALS, INC. 2011-08-25 US disclosed
US-20110207716-A1 INHIBITORS OF POLO-LIKE KINASE ELAN PHARMACEUTICALS, INC. 2011-08-25 US disclosed
US-20110207716-A1 INHIBITORS OF POLO-LIKE KINASE ELAN PHARMACEUTICALS, INC. 2011-08-25 US disclosed
WO-2011079118-A1 PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE ELAN PHARMACEUTICALS, INC (US) 2011-06-30 WO disclosed
WO-2011079118-A1 PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE ELAN PHARMACEUTICALS, INC (US) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331376-A1 INHIBITORS OF POLO-LIKE KINASE PLK1, POLK, POLR2E PLK1 1/4885PLK2 22/4885PLK3 101/4885
US-20110207716-A1 INHIBITORS OF POLO-LIKE KINASE PLK1, POLK, POLR2E PLK1 1/4885PLK2 22/4885PLK3 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.